Efficacy and safety of on-demand tadalafil for the treatment of erectile dysfunction in South-East Asian men

• Published in: International journal of urology Vol. 13; no. 6; pp. 721 - 727
• Main Authors: GUO, YING LU, ZHU, JI CHUAN, PAN, TIAN MING, DING, QIANG, WANG, YI XIN, CHEONG, NG FOO, LIM, EDWIN, SHEN, WEI, VENUGOPALAN, MURALI, CHAN, MELANIE
• Format: Journal Article
• Language: English
• Published: Melbourne, Australia Blackwell Publishing Asia 01-06-2006
• Subjects: Adult; Aged; Aged, 80 and over; Asia, Southeastern; Asian men; Carbolines - administration & dosage; Carbolines - adverse effects; clinical trial; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; efficacy; erectile dysfunction; Erectile Dysfunction - drug therapy; Humans; Male; Middle Aged; Penile Erection - drug effects; phosphodiesterase 5 inhibitor; Phosphodiesterase Inhibitors - administration & dosage; Phosphodiesterase Inhibitors - adverse effects; Tadalafil; Asia, Southeastern
• ISSN: 0919-8172; 1442-2042
• DOI: 10.1111/j.1442-2042.2006.01393.x

Aim:  Tadalafil is an inhibitor of phosphodiesterase type 5 used for the treatment of erectile dysfunction (ED). The efficacy and safety of tadalafil have been evaluated extensively in Western populations. Our aim was to assess the efficacy and safety of on‐demand tadalafil for the treatment of ED in South‐East Asian men.
Methods:  This was a randomized, double‐blind, placebo‐controlled study of men with mild to severe ED of various etiologies randomized to receive placebo (n = 122), tadalafil 10 mg (n = 120), or tadalafil 20 mg (n = 125), taken as needed (maximum once daily) for 12 weeks. Efficacy assessments included the International Index of Erectile Function (IIEF), the Sexual Encounter Profile (SEP) diary, and a Global Assessment Question (GAQ).
Results:  Men from China, Singapore, and the Philippines participated in this trial (n = 367). Compared with placebo, tadalafil significantly improved erectile dysfunction on all efficacy outcomes (P < 0.001). Patients receiving tadalafil 10 mg and 20 mg experienced a significant mean improvement of 8.1 and 8.7, respectively, in the IIEF Erectile Function (IIEF‐EF) domain score from baseline (vs placebo 2.4, P < 0.001). In patients receiving tadalafil 10 mg and 20 mg, the mean per‐patient success rate for intercourse attempts (SEP3) was 62% and 70%, respectively, compared with 32% for the placebo group (P < 0.001). Of patients who received tadalafil 10 mg and 20 mg, 81% and 86% reported improved erections at endpoint (GAQ) compared with 44% in the placebo group (P < 0.001). The most common adverse events reported by patients were headache, back pain, dyspepsia, and dizziness.
Conclusions:  Tadalafil was an effective and well‐tolerated treatment for South‐East Asian men with ED.